Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

S100A4 amplifies TGF-β-induced fibroblast activation in systemic sclerosis

M. Tomcik, K. Palumbo-Zerr, P. Zerr, J. Avouac, C. Dees, B. Sumova, A. Distler, C. Beyer, LA. Cerezo, R. Becvar, O. Distler, M. Grigorian, G. Schett, L. Senolt, JH. Distler,

. 2015 ; 74 (9) : 1748-55. [pub] 20140407

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16000772

OBJECTIVES: S100A4 is a calcium binding protein with regulatory functions in cell homeostasis, proliferation and differentiation that has been shown to promote cancer progression and metastasis. In the present study, we evaluated the role of S100A4 in fibroblast activation in systemic sclerosis (SSc). METHODS: The expression of S100A4 was analysed in human samples, murine models of SSc and in cultured fibroblasts by real-time PCR, immunohistochemistry and western blot. The functional role of S100A4 was evaluated using siRNA, overexpression, recombinant protein and S100A4 knockout (S100A4(-/-)) mice. Transforming growth factor β (TGF-β) signalling was assessed by reporter assays, staining for phosphorylated Smad2/3 and analyses of target genes. RESULTS: The expression of S100A4 was increased in SSc skin and in experimental fibrosis in a TGF-β/Smad-dependent manner. Overexpression of S100A4 or stimulation with recombinant S100A4 induced an activated phenotype in resting normal fibroblasts. In contrast, knockdown of S100A4 reduced the pro-fibrotic effects of TGF-β and decreased the release of collagen. S100A4(-/-) mice were protected from bleomycin-induced skin fibrosis with reduced dermal thickening, decreased hydroxyproline content and lower myofibroblast counts. Deficiency of S100A4 also ameliorated fibrosis in the tight-skin-1 (Tsk-1) mouse model. CONCLUSIONS: We characterised S100A4 as a downstream mediator of the stimulatory effects of TGF-β on fibroblasts in SSc. TGF-β induces the expression of S100A4 to stimulate the release of collagen in SSc fibroblasts and induce fibrosis. Since S100A4 is essentially required for the pro-fibrotic effects of TGF-β and neutralising antibodies against S100A4 are currently evaluated, S100A4 might be a candidate for novel antifibrotic therapies.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16000772
003      
CZ-PrNML
005      
20160121123231.0
007      
ta
008      
160108s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/annrheumdis-2013-204516 $2 doi
035    __
$a (PubMed)24709861
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Tomcik, Michal $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany Department of Rheumatology, 1st Faculty of Medicine, Institute of Rheumatology, Charles University, Prague, Czech Republic.
245    10
$a S100A4 amplifies TGF-β-induced fibroblast activation in systemic sclerosis / $c M. Tomcik, K. Palumbo-Zerr, P. Zerr, J. Avouac, C. Dees, B. Sumova, A. Distler, C. Beyer, LA. Cerezo, R. Becvar, O. Distler, M. Grigorian, G. Schett, L. Senolt, JH. Distler,
520    9_
$a OBJECTIVES: S100A4 is a calcium binding protein with regulatory functions in cell homeostasis, proliferation and differentiation that has been shown to promote cancer progression and metastasis. In the present study, we evaluated the role of S100A4 in fibroblast activation in systemic sclerosis (SSc). METHODS: The expression of S100A4 was analysed in human samples, murine models of SSc and in cultured fibroblasts by real-time PCR, immunohistochemistry and western blot. The functional role of S100A4 was evaluated using siRNA, overexpression, recombinant protein and S100A4 knockout (S100A4(-/-)) mice. Transforming growth factor β (TGF-β) signalling was assessed by reporter assays, staining for phosphorylated Smad2/3 and analyses of target genes. RESULTS: The expression of S100A4 was increased in SSc skin and in experimental fibrosis in a TGF-β/Smad-dependent manner. Overexpression of S100A4 or stimulation with recombinant S100A4 induced an activated phenotype in resting normal fibroblasts. In contrast, knockdown of S100A4 reduced the pro-fibrotic effects of TGF-β and decreased the release of collagen. S100A4(-/-) mice were protected from bleomycin-induced skin fibrosis with reduced dermal thickening, decreased hydroxyproline content and lower myofibroblast counts. Deficiency of S100A4 also ameliorated fibrosis in the tight-skin-1 (Tsk-1) mouse model. CONCLUSIONS: We characterised S100A4 as a downstream mediator of the stimulatory effects of TGF-β on fibroblasts in SSc. TGF-β induces the expression of S100A4 to stimulate the release of collagen in SSc fibroblasts and induce fibrosis. Since S100A4 is essentially required for the pro-fibrotic effects of TGF-β and neutralising antibodies against S100A4 are currently evaluated, S100A4 might be a candidate for novel antifibrotic therapies.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a zvířata $7 D000818
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fibroblasty $x metabolismus $7 D005347
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a myši knockoutované $7 D018345
650    _2
$a lidé středního věku $7 D008875
650    _2
$a proteiny S100 $x metabolismus $7 D009418
650    _2
$a systémová sklerodermie $x metabolismus $7 D012595
650    _2
$a kůže $x metabolismus $7 D012867
650    _2
$a protein Smad2 $x metabolismus $7 D051899
650    _2
$a protein Smad3 $x metabolismus $7 D051900
650    _2
$a transformující růstový faktor beta $x metabolismus $7 D016212
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Palumbo-Zerr, Katrin $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Zerr, Pawel $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Avouac, Jerome $u Rheumatology A Department, Paris Descartes University, Cochin Hospital, Paris, France. $7 gn_A_00010388
700    1_
$a Dees, Clara $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Sumova, Barbora $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany Department of Rheumatology, 1st Faculty of Medicine, Institute of Rheumatology, Charles University, Prague, Czech Republic.
700    1_
$a Distler, Alfiya $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Beyer, Christian $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Cerezo, Lucie Andres $u Department of Rheumatology, 1st Faculty of Medicine, Institute of Rheumatology, Charles University, Prague, Czech Republic.
700    1_
$a Becvar, Radim $u Department of Rheumatology, 1st Faculty of Medicine, Institute of Rheumatology, Charles University, Prague, Czech Republic.
700    1_
$a Distler, Oliver $u Center of Experimental Rheumatology and Zurich Center of Integrative Human Physiology, University Hospital, Zurich, Switzerland.
700    1_
$a Grigorian, Mariam $u Neuro-Oncology Group, Faculty of Health Sciences, Institute of Neuroscience and Pharmacology, Copenhagen University, Copenhagen, Denmark.
700    1_
$a Schett, Georg $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Senolt, Ladislav $u Department of Rheumatology, 1st Faculty of Medicine, Institute of Rheumatology, Charles University, Prague, Czech Republic.
700    1_
$a Distler, Jörg H W $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
773    0_
$w MED00000444 $t Annals of the rheumatic diseases $x 1468-2060 $g Roč. 74, č. 9 (2015), s. 1748-55
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24709861 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160108 $b ABA008
991    __
$a 20160121123350 $b ABA008
999    __
$a ok $b bmc $g 1103053 $s 924978
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 74 $c 9 $d 1748-55 $e 20140407 $i 1468-2060 $m Annals of the rheumatic diseases $n Ann Rheum Dis $x MED00000444
LZP    __
$a Pubmed-20160108

Find record

Citation metrics

Logged in users only

Archiving options